iCAD develops artificial intelligence solutions for medical imaging, with a central focus on improving the detection of breast cancer. Founded in 1984, the company applies computer vision and machine learning to help healthcare providers analyze medical images more accurately and efficiently. Its technology is used in clinical settings across more than 50 countries.
The company's primary offering is the ProFound Breast Health Suite, a portfolio of AI-driven tools designed for breast cancer detection, automated breast density assessment, and personalized short-term risk evaluation. iCAD's systems have been used to analyze over 40 million mammograms worldwide, and the company's technology is involved in nearly 30% of digital breast tomosynthesis exams conducted in its markets.
Based in Nashua, New Hampshire, iCAD operates at the intersection of medical technology, radiology, and oncology. The company is part of DeepHealth and states its mission is to make AI-powered mammography more widely accessible, aiming to advance early cancer detection on a global scale.
